Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Endothelial Cells in Inflammation, Tissue Repair, Ageing and Cancer
share announcement

Endothelial Cells in Inflammation, Tissue Repair, Ageing and Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Tumor Microenvironment".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 14476

Special Issue Editors

Prof. Dr. Evangelia Papadimitriou

E-Mail Website
Guest Editor
Department of Pharmacy, University of Patras, 26504 Rion, Greece
Interests: angiogenesis; endothelial cells; growth factors; tyrosine kinases; tyrosine phosphatases; cell signaling
Prof. Dr. Constantinos Mikelis

E-Mail Website
Guest Editor
Department of Pharmacy, University of Patras, 26504 Rion, Greece
Interests: vascular biology; angiogenesis; metastasis; small GTPases; RhoA
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Inflammation is a physiological process that confers protection from pathogen infections but also accompanies many pathological situations as well as ageing. The endothelial cells are important players in this process, as they regulate neovascular formation and present increased leakiness, enabling the transmigration of the immune cells outside of vessels. The endothelial cells regulate the inflammatory outcome, though many aspects of their role and the impact of their mediators have not been fully elucidated.

Ageing is an inevitable biological process for all organisms and is orchestrated by sophisticated signaling pathways in numerous types of cells. Endothelial cells and angiogenesis seem to have a leading role in this process that also includes activated inflammatory pathways. Similarly, tissue repair also activates inflammatory pathways that provide the necessary stimuli to initiate angiogenesis and help restore the damaged tissues.

Tumor is an inflammatory disease. The role of the tumor microenvironment for tumor progression and metastatic dissemination has been established. The endothelial cells, as part of the tumoral and peritumoral vasculature, play a pivotal role in the recruitment of new vessels, enabling tumor growth, while the leakiness of the newly formed vessels augments the metastatic dissemination. Despite the advances, the temporary effect of anti-angiogenic treatments and the lack of anti-metastatic approaches are pitfalls in the development of new anticancer drugs. Moreover, the impact of the novel anti-tumor immunotherapeutic approaches on endothelial cell physiology has not been fully explored.

In this Special Issue, we highlight the role of the endothelial functions in inflammatory diseases, including tumors, covering both basic and preclinical data that can advance our understanding on endothelial physiology in these conditions.

Prof. Dr. Evangelia Papadimitriou
Prof. Dr. Constantinos Mikelis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ageing
  • angiogenesis
  • cancer
  • cytokines
  • endothelial cells
  • growth factors
  • inflammation
  • tissue repair

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

22 pages, 27185 KiB  
Article
Spatial Distribution of Non-Immune Cells Expressing Glycoprotein A Repetitions Predominant in Human and Murine Metastatic Lymph Nodes
by Loïc Rouaud, Louis Baudin, Marine Gautier-Isola, Pierre Van Meerbeeck, Emilie Feyereisen, Silvia Blacher, Nicolas van Baren, Frédéric Kridelka, Sophie Lucas and Agnes Noel
Cancers 2023, 15(23), 5621; https://doi.org/10.3390/cancers15235621 - 28 Nov 2023
Viewed by 1026
Abstract
Several types of cancer spread through the lymphatic system via the sentinel lymph nodes (LNs). Such LN-draining primary tumors, modified by tumor factors, lead to the formation of a metastatic niche associated with an increased number of Foxp3+ regulatory T cells (Tregs). These [...] Read more.
Several types of cancer spread through the lymphatic system via the sentinel lymph nodes (LNs). Such LN-draining primary tumors, modified by tumor factors, lead to the formation of a metastatic niche associated with an increased number of Foxp3+ regulatory T cells (Tregs). These cells are expected to contribute to the elaboration of an immune-suppressive environment. Activated Tregs express glycoprotein A repetitions predominant (GARP), which binds and presents latent transforming growth factor beta 1 (TGF-β1) at their surface. GARP is also expressed by other non-immune cell types poorly described in LNs. Here, we mapped GARP expression in non-immune cells in human and mouse metastatic LNs. The mining of available (human and murine) scRNA-Seq datasets revealed GARP expression by blood (BEC)/lymphatic (LEC) endothelial, fibroblastic, and perivascular cells. Consistently, through immunostaining and in situ RNA hybridization approaches, GARP was detected in and around blood and lymphatic vessels, in (αSMA+) fibroblasts, and in perivascular cells associated with an abundant matrix. Strikingly, GARP was detected in LECs forming the subcapsular sinus and high endothelial venules (HEVs), two vascular structures localized at the interface between LNs and the afferent lymphatic and blood vessels. Altogether, we here provide the first distribution maps for GARP in human and murine LNs. Full article
(This article belongs to the Special Issue Endothelial Cells in Inflammation, Tissue Repair, Ageing and Cancer)
►▼ Show Figures

Figure 1

Review

Jump to: Research

36 pages, 2828 KiB  
Review
Diagnosis, Prognosis, and Treatment of Canine Hemangiosarcoma: A Review Based on a Consensus Organized by the Brazilian Association of Veterinary Oncology, ABROVET
by Andrigo Barboza De Nardi, Cristina de Oliveira Massoco Salles Gomes, Carlos Eduardo Fonseca-Alves, Felipe Noleto de Paiva, Laís Calazans Menescal Linhares, Gabriel João Unger Carra, Rodrigo dos Santos Horta, Felipe Augusto Ruiz Sueiro, Paulo Cesar Jark, Adriana Tomoko Nishiya, Carmen Helena de Carvalho Vasconcellos, Rodrigo Ubukata, Karen Batschinski, Renata Afonso Sobral, Simone Crestoni Fernandes, Luiz Roberto Biondi, Ricardo De Francisco Strefezzi, Julia Maria Matera, Marcelo Monte Mor Rangel, Denner Santos dos Anjos, Carlos Henrique Maciel Brunner, Renee Laufer-Amorim, Karine Germano Cadrobbi, Juliana Vieira Cirillo, Mauro Caldas Martins, Nazilton de Paula Reis Filho, Diego Fernando Silva Lessa, Roberta Portela, Carolina Scarpa Carneiro, Sílvia Regina Ricci Lucas, Heidge Fukumasu, Marcus Antônio Rossi Feliciano, Juliany Gomes Quitzan and Maria Lucia Zaidan Dagliadd Show full author list remove Hide full author list
Cancers 2023, 15(7), 2025; https://doi.org/10.3390/cancers15072025 - 29 Mar 2023
Cited by 5 | Viewed by 12994
Abstract
Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, [...] Read more.
Hemangiosarcoma is a mesenchymal neoplasm originating in the endothelial cells of blood vessels; they can be classified as non-visceral and visceral types. Non-visceral hemangiosarcomas can affect the skin, subcutaneous tissues, and muscle tissues; visceral hemangiosarcomas can affect the spleen, liver, heart, lungs, kidneys, oral cavity, bones, bladder, uterus, tongue, and retroperitoneum. Among domestic species, dogs are most affected by cutaneous HSA. Cutaneous HSA represents approximately 14% of all HSA diagnosed in this species and less than 5% of dermal tumors, according to North American studies. However, Brazilian epidemiological data demonstrate a higher prevalence, which may represent 27 to 80% of all canine HSAs and 13.9% of all skin neoplasms diagnosed in this species. Cutaneous HSA most commonly affects middle-aged to elderly dogs (between 8 and 15 years old), with no gender predisposition for either the actinic or non-actinic forms. The higher prevalence of cutaneous HSA in some canine breeds is related to lower protection from solar radiation, as low skin pigmentation and hair coverage lead to greater sun exposure. Actinic changes, such as solar dermatosis, are frequent in these patients, confirming the influence of solar radiation on the development of this neoplasm. There are multiple clinical manifestations of hemangiosarcoma in canines. The diagnostic approach and staging classification of cutaneous HSAs are similar between the different subtypes. The definitive diagnosis is obtained through histopathological analysis of incisional or excisional biopsies. Cytology can be used as a presurgical screening test; however, it has little diagnostic utility in cases of HSA because there is a high risk of blood contamination and sample hemodilution. Surgery is generally the treatment of choice for dogs with localized non-visceral HSA without evidence of metastatic disease. Recently, electrochemotherapy (ECT) has emerged as an alternative therapy for the local ablative treatment of different neoplastic types; the use of radiotherapy for the treatment of dogs with cutaneous HSA is uncommon. There is greater consensus in the literature regarding the indications for adjuvant chemotherapy in subcutaneous and muscular HSA; doxorubicin is the most frequently used antineoplastic agent for subcutaneous and muscular subtypes and can be administered alone or in combination with other drugs. Other therapies include antiangiogenic therapy, photodynamic therapy, the association of chemotherapy with the metronomic dose, targeted therapies, and natural products. The benefits of these therapies are presented and discussed. In general, the prognosis of splenic and cardiac HSA is unfavorable. As a challenging neoplasm, studies of new protocols and treatment modalities are necessary to control this aggressive disease. Full article
(This article belongs to the Special Issue Endothelial Cells in Inflammation, Tissue Repair, Ageing and Cancer)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop